Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.57 |
| ▸ | NPC1 | O15118 | 8/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.57 |
| ▸ | AR | P10275 | 2/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.49 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | TP53 | P04637 | 3/20 | 0.48 |
| ▸ | PKM | P14618 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Anthracene SCHEMBL29215201 | 0.94 | RAB9A (0.52) | RAB9ANPC1CYP3A4CYP1A2AR | |
| SCHEMBL24184547 | 0.84 | RAB9A (0.61) | RAB9ANPC1CYP3A4CYP1A2AR | |
| 2-Phenylquinoline SCHEMBL27928466 | 0.83 | RAB9A (0.62) | RAB9ANPC1CYP3A4CYP1A2AR | |
| Hydrochloric Acid SCHEMBL2415958 | 0.81 | RAB9A (0.65) | RAB9ANPC1CYP3A4CYP1A2AR | |
| Hydrochloric Acid SCHEMBL10653147 | 0.81 | RAB9A (0.65) | RAB9ANPC1CYP3A4CYP1A2AR | |
| SCHEMBL10596816 | 0.81 | CYP1A2 (0.55) | RAB9ANPC1CYP3A4CYP1A2AR | |
| SCHEMBL29374931 | 0.81 | RAB9A (0.64) | RAB9ANPC1CYP3A4CYP1A2AR | |
| SCHEMBL170196 | 0.81 | RAB9A (0.64) | RAB9ANPC1CYP3A4CYP1A2AR | |
| SCHEMBL29496173 | 0.81 | KDM4E (0.61) | RAB9ANPC1CYP3A4CYP1A2AR | |
| SCHEMBL29746183 | 0.81 | KDM4E (0.61) | RAB9ANPC1CYP3A4CYP1A2AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050192293-A1 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. | 2005-09-01 | — | — | US | claimed |
| WO-2005034870-A2 | AMIDE COMPOUNDS AND ION CHANNEL LIGANDS AND USES THEREOF | RENOVIS, INC. (US) | 2005-04-21 | — | — | WO | claimed |
| CN-117777094-A | Anthracene compound and organic electroluminescent device comprising same | 石家庄诚志永华显示材料有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-117777202-A | Pyrene compound and organic electroluminescent device comprising pyrene compound | 石家庄诚志永华显示材料有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-108314647-B | Preparation method of quinoline-2-formic acid and quinoline-2-formic acid derivative | 华中科技大学 | 2020-06-26 | — | — | CN | disclosed |
| CN-105793779-A | Molecular glass mixtures for organic electronics applications | 分子玻璃公司 | 2016-07-20 | — | — | CN | disclosed |
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | KELLY MICHAEL G | 2008-08-21 | — | — | US | disclosed |
| US-7338950-B2 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
| EP-1339706-B1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2006-04-19 | — | — | EP | disclosed |
| US-20050192293-A1 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. | 2005-09-01 | — | — | US | disclosed |
| WO-2005034870-A2 | AMIDE COMPOUNDS AND ION CHANNEL LIGANDS AND USES THEREOF | RENOVIS, INC. (US) | 2005-04-21 | — | — | WO | disclosed |
| US-6815447-B2 | 6-N-(2-AMINO-PYRIMIDIN-4-YL)QUINOLINE-6-AMINE DERIVATIVES; ANALGESICS | ASTRAZENECA AB (SE) | 2004-11-09 | — | — | US | disclosed |
| US-20040058945-A1 | N-type calcium channel antagonists for the treatment of pain | CHAUDHARI BIPINCHANDRA (US) | 2004-03-25 | — | — | US | disclosed |
| EP-1339706-A1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002036586-A1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2002-05-10 | — | — | WO | disclosed |
| EP-1015444-A1 | NOVEL PYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION, LTD. (KR) | 2000-07-05 | — | — | EP | disclosed |
| WO-1998043968-A1 | NOVEL PYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | YUHAN CORPORATION (KR) | 1998-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | TRPV1, TRPA1, TRPV2 | RAB9A 1914/4885NPC1 1061/4885CYP3A4 3342/4885 |
| US-20050192293-A1 | Amide compounds as ion channel ligands and uses thereof | TRPV1, TRPA1, TRPV2 | RAB9A 1914/4885NPC1 1061/4885CYP3A4 3342/4885 |
| US-20040058945-A1 | N-type calcium channel antagonists for the treatment of pain | CACNA1E, CACNA1B, CACNA1A | RAB9A 2083/4885NPC1 1452/4885CYP3A4 4381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.